New combo for tough lung cancer shows promise in early trial

NCT ID NCT05469178

Terminated Disease control Sponsor: BerGenBio ASA Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times

Summary

This study tested a new drug called bemcentinib combined with standard chemotherapy and immunotherapy for people with advanced non-squamous non-small cell lung cancer. The goal was to find a safe dose and see if the combination could shrink tumors, especially in patients with a specific gene change (STK11 mutation). The trial was stopped early, but results help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi

Bologna, 40138, Italy
Centre Antoine Lacassagne

Nice, 6189, France
Duke University Medical Center - Duke Cancer Center

Durham, North Carolina, 27710, United States
Fejer County St. Gyorgy Hospital

Székesfehérvár, 8000, Hungary
Fundacion Instituto Valenciano de Oncologia (FIVO)

Valencia, 46009, Spain
General Hospital of Athens Alexandra, Department of the Clinical Therapeutics, Medical Oncology Unit

Athens, 11528, Greece
Henry Dunant Hospital Center, 4th Oncology Department

Athens, 115 26, Greece
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Universitari Germans Trias i Pujol

Badalona, 8916, Spain
Hospital Universitario Fundacion Jimenez Diaz

Madrid, 28040, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 8035, Spain
Hôpital Europeen Georges Pompidou (HEGP), Service de cancérologie

Paris, 75015, France
Hôpital prive du Confluent SAS, Departement d'oncologie

Nantes, 44277, France
IFO Regina Elena

Rome, 144, Italy
IRCCS - Istituto Europeo di Oncologia IEO

Milan, 20141, Italy
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Institut Gustave Roussy, Service de médecine

Villejuif, 94805, France
Instytut Centrum Zdrowia Matki Polki (ICZMP)

Lodz, 93-338, Poland
MD Anderson Cancer Center, Oncology service

Madrid, 28033, Spain
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland

Baltimore, Maryland, 21201, United States
MedPolonia Sp z oo

Poznan, 60693, Poland
Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, 33140, United States
Orszagos Koranyi Pulmonologiai Intezet

Budapest, 1121, Hungary
Ospedale San Luca

Lucca, 55100, Italy
Semmelweis University- Department of Pulmonology

Budapest, 1083, Hungary
Sotiria General Hospital of Chest Diseases, 3rd Department of Internal Medicine, Oncology Unit

Athens, 115 27, Greece
Tennessee Oncology PLLC

Nashville, Tennessee, 37203, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University General Hospital of Larissa, Oncology Clinic

Larissa, 41110, Greece
University of Chicago

Chicago, Illinois, 60637, United States
Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie

Lublin, 20090, Poland
Uniwersytecki Szpital Kliniczny w Bialymstoku, II Klinika Chorob Pluc, raka płuca i chorób wewnętrznych

Bialystok, 15-540, Poland

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG